02:36 , Aug 24, 2018 |  BC Innovations  |  Targets & Mechanisms

Computing checkpoints

After 25 years as a discovery company, Compugen Ltd. is about to enter the clinic for the first time with a first-in-class mAb against a new checkpoint target. The target’s expression on adaptive immune cells,...
00:28 , Mar 31, 2017 |  BC Innovations  |  Targets & Mechanisms

Cells on the rise

This year’s meeting of the American Association for Cancer Research (AACR) will keep the spotlight on immuno-oncology, where preclinical science is continuing to expand the use of different types of innate and adaptive immune cells...
07:00 , May 28, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Clostridium difficile toxin B (TcdB); poliovirus receptor-related 3 (PVRL3)

Infectious disease INDICATION: Clostridium Cell culture studies suggest inhibiting the TcdB- PVRL3 interaction could help treat Clostridium difficile infection. In a human colon epithelial cell line treated with TcdB , PVRL3 knockout increased cell survival...